Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition - 11/01/12
Corresponding author.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
To assess the efficacy of abatacept in patients with axial spondyloarthropathies who had failed TNF⍺ antagonist therapy.
Methods |
Consecutive patients fulfilling criteria for active axial spondyloarthropathy, despite at least two previous TNF⍺ antagonists, were treated with abatacept (10mg/kg) given on days 1, 15, and 29, then every 28days until week 24. Clinical and laboratory outcome criteria were assessed monthly for 6months.
Results |
Seven patients were treated and followed, all women (median age, 39years; median disease duration, 12years), five with ankylosing spondylitis and two with undifferentiated spondyloarthropathy. After 6months of abatacept therapy, no patient had an at least 50% decrease in the BASDAI; a single patient had an at least 2cm decrease in the BASDAI (−3.8cm; −49.3%). No significant changes were observed in pain or patient global assessment scores. Inflammatory back pain persisted in all seven patients. When present, enthesitis improved in most patients. Improvements in spinal mobility measures occurred in two patients. There were no clinically significant adverse events.
Conclusion |
A 6-month regimen of abatacept did not meaningfully improve disease activity, function, or other disease parameters in seven patients with axial spondyloarthropathies. These preliminary results do not suggest a strong efficacy of abatacept in axial forms of spondyloarthropathies.
Le texte complet de cet article est disponible en PDF.Keywords : Abatacept, Spondylarthropathies, Ankylosing spondylitis, Psoriatic arthritis, Biotherapy
Plan
Vol 79 - N° 1
P. 47-50 - janvier 2012 Retour au numéro
Article précédent
- Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort
- Karima Benbouazza, Hanan Rkain, Bahia Benchekroun, Bouchra Amine, Fatiha Bzami, Leila Benbrahim, Ouafa Atouf, Malika Essakalli, Redouane Abouqal, Maxime Dougados, Najia Hajjaj-Hassouni
- Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap
- Tamer A. Gheita, Hani Hussein
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?